Ipamorelin vs MK-677
Comprehensive side-by-side comparison of mechanisms, dosing, side effects, and research
Also: IPAM, NNC 26-0161
A selective growth hormone secretagogue that stimulates GH release without significantly affecting cortisol or prolactin. Considered one of the safest GHRPs.
Also: Ibutamoren, Nutrobal
An orally active growth hormone secretagogue that mimics ghrelin. Although technically not a peptide, it is frequently discussed alongside GH peptides due to similar effects.
Key Comparison Insights
- Both peptides belong to the Growth Hormone category, suggesting similar primary applications.
Detailed Comparison
| Attribute | Ipamorelin | MK-677 |
|---|---|---|
| Category | Growth Hormone | Growth Hormone |
| FDA Status | Not FDA Approved | Not FDA Approved |
| Clinical Status | Pre I II III IV FDA | Pre I II III IV FDA |
| Mechanism of Action | Ipamorelin binds to ghrelin receptors (GHSR) in the pituitary gland, triggering growth hormone release. Unlike other GHRPs, it does not stimulate significant ACTH, cortisol, prolactin, or aldosterone release, making it highly selective for GH. | MK-677 binds to ghrelin receptors (GHSR) in the brain, stimulating sustained GH release and increasing IGF-1 levels. Unlike injectable GHRPs, it is orally bioavailable and has a long half-life providing 24-hour GH elevation. |
| Common Dosing | 200-300 mcg 2-3x daily 2-3x daily | 10-25 mg daily Once daily, often before bed |
| Administration | Subcutaneous injection | Oral |
| Typical Duration | 8-12 weeks typical | 8-12 weeks or longer |
| Best Time to Take | Before bed or morning (fasted) | Before bed |
Possible Side Effects May vary by individual |
|
|
| Research Summary | Phase II trials for postoperative ileus showed good safety but failed to meet efficacy endpoints and were discontinued. Research demonstrates dose-dependent GH release with minimal side effects, improved bone density in postmenopausal women, and potential benefits for muscle mass and recovery. | Studies show increases in GH and IGF-1 levels, improved sleep quality, and increased lean body mass. However, a clinical trial was stopped early due to heart failure concerns in elderly patients. FDA lists MK-677 as having 'significant safety risks due to potential for congestive heart failure.' December 2025: FDA issued warning letters to companies selling MK-677. Never received FDA approval and remains an unapproved drug. |
Frequently Asked Questions: Ipamorelin vs MK-677
What is the difference between Ipamorelin and MK-677?
Ipamorelin is a growth hormone peptide that a selective growth hormone secretagogue that stimulates gh release without significantly affecting cortisol or prolactin. considered one of the safest ghrps. MK-677 is a growth hormone peptide that an orally active growth hormone secretagogue that mimics ghrelin. although technically not a peptide, it is frequently discussed alongside gh peptides due to similar effects. The main differences lie in their mechanisms of action and clinical applications.
Which is better, Ipamorelin or MK-677?
Neither is universally "better" - the choice depends on your specific goals. Ipamorelin is typically used for growth hormone purposes, while MK-677 is used for growth hormone. Always consult with a healthcare provider to determine which may be appropriate for your situation.
Can Ipamorelin and MK-677 be used together?
Some peptide protocols combine multiple compounds for synergistic effects. However, using Ipamorelin and MK-677 together should only be considered under medical supervision, as both compounds have their own side effect profiles and potential interactions. Research on their combined use may be limited.